NIH Highlighted Topic: Drug Discovery for Nervous System Disorders
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on accelerating drug discovery for nervous system disorders through novel therapeutics, advanced screening technologies, computational modeling, and AI-enabled drug development approaches. This highlighted topic supports projects aimed at discovering and optimizing small molecules, biologics, and therapeutic platforms targeting the underlying molecular and cellular mechanisms of neurological and neuropsychiatric diseases.
NIH is particularly interested in projects targeting neuronal dysfunction, neuroinflammation, synaptic plasticity, neural connectivity, protein aggregation, neurotransmitter systems, ion channels, neural-glial communication, oxidative stress, and other biological mechanisms associated with nervous system disorders. Companies developing AI-powered drug discovery platforms, neurotherapeutics, computational biology tools, medicinal chemistry technologies, biologics, or advanced CNS delivery systems may be strong candidates for funding.
Areas of interest include high-throughput screening systems, virtual screening, machine learning-assisted lead optimization, medicinal chemistry, naturally derived therapeutic compounds, DMPK and toxicity studies, preclinical efficacy validation, and novel brain-targeted delivery technologies. NIH is also encouraging projects focused on Alzheimer’s disease, dementia, substance use disorders, mental health conditions, neurodevelopmental disorders, and visual system diseases.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and translational impact.
This highlighted topic is supported by several NIH Institutes including the National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Drug Abuse (NIDA), and National Institute of Mental Health (NIMH), all of which are seeking transformative innovations that improve therapeutic discovery and treatment outcomes for nervous system disorders.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of therapeutics, drug discovery technologies, computational platforms, biologics, and neurotechnology solutions related to nervous system disorders.
Eligible activities may include:
AI and machine learning platforms for CNS drug discovery
High-throughput and virtual compound screening technologies
Medicinal chemistry and lead optimization research
Development of biologics and small molecule therapeutics
Computational biology and molecular modeling systems
Drug-target interaction and protein aggregation analysis tools
Preclinical efficacy studies and disease model validation
DMPK, pharmacokinetic, and toxicity assessment technologies
Novel brain-targeted drug delivery systems
Therapeutics for Alzheimer’s disease and dementia
Neuropsychiatric and mental health therapeutic development
Substance use disorder and addiction treatment platforms
Ophthalmic and visual system therapeutic technologies
Neural-glial communication and synaptic plasticity research tools
Biomarker discovery and translational neuroscience platforms
Natural product discovery and characterization systems
Prototype development, validation studies, and translational research
Commercialization planning, regulatory preparation, and scale-up activities
Funding may also support personnel, laboratory testing, medicinal chemistry, AI model development, cloud computing infrastructure, software development, preclinical studies, bioinformatics, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable therapeutic or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
